- Home
- »
- Medical Devices
- »
-
Healthcare Analytical Testing Services Market Report, 2026-2033GVR Report cover
Healthcare Analytical Testing Services Market (2026 - 2033)
Size, Share & Trends Analysis Report By Type (Medical Device Analytical Testing Services, Pharmaceutical Analytical Testing Services), By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts
Market Size, 2025
$17.0BMarket Estimate, 2026
$18.4BMarket Forecast, 2033
$32.7BCAGR, 2026–2033
8.5%Healthcare Analytical Testing Services Market Summary
The global healthcare analytical testing services market size was valued at USD 17.0 billion in 2025 and is projected to grow from USD 18.4 billion in 2026 to USD 32.7 billion by 2033, at a CAGR of 8.5% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 39.2% in 2025. The healthcare analytical testing services industry is experiencing sustained growth driven by increasing pharmaceutical and biotechnology research activities, expanding biologics and biosimilars pipelines, rising outsourcing of analytical testing services, stringent global regulatory requirements, and continuous advancements in analytical technologies.
Source: Grand View Research, IR Documents, Primary Interviews, Paid DatabasesTo learn more about this report,
Download Free Sample Report Key Market Trends & Insights
- By type: Pharmaceutical analytical testing services held the largest revenue share of 58.4% in 2025.
Regional Highlights
- Largest regional market: North America (39.2% revenue share, 2025)
- Fastest-growing regional market: Asia Pacific (fastest CAGR, 2026-2033)
- By country: The U.S. is expected to grow significantly from 2026 to 2033
Market Size & Forecast
- Market size in 2025: USD 17.0 Billion
- Estimated market size in 2026: USD 18.4 Billion
- Projected market size by 2033: USD 32.7 Billion
- CAGR (2026-2033): 8.5%
Prism AI by Grand View Research Free to tryAsk a question about the healthcare analytical testing services marketTry asking✓Every figure cited from GVR research Prefer the report? Download free sample →
Growing investments in cell and gene therapies, antibody drug conjugates, RNA therapeutics, and personalized medicines are further increasing demand for specialized analytical capabilities across the product development lifecycle. Pharmaceutical companies are seeking faster development timelines while maintaining regulatory compliance, leading to greater adoption of outsourced testing services that offer advanced instrumentation and scientific expertise. One of the primary growth factors is the rapid expansion of biologics and other complex therapeutics. Biologics require extensive characterization, impurity profiling, stability assessment, bioanalytical studies, and comparability testing before regulatory approval.
To learn more about this report, Download Free Sample Report Such products involve sophisticated molecular structures and greater manufacturing variability than conventional small-molecule drugs, creating demand for highly specialized analytical laboratories equipped with advanced chromatography, mass spectrometry, spectroscopy, and molecular biology platforms. For instance, in October 2025, Eurofins Viracor BioPharma Services commenced operations at a renovated 8,800 m² laboratory in Lenexa, Kansas, expanding specialty bioanalytical and biomarker testing capabilities for infectious diseases, oncology, autoimmune disorders, cell and gene therapies, and biologics, while adding LCMS bioanalytical capacity for both large and small molecule drug development.
In addition, the increasing outsourcing of analytical testing by pharmaceutical, biotechnology, and medical device manufacturers. Many companies prefer external analytical laboratories to gain access to specialized expertise, validated analytical methods, regulatory knowledge, and advanced instrumentation without making substantial capital investments. Outsourcing also enables manufacturers to optimize operational costs, improve laboratory efficiency, and accelerate regulatory submissions while focusing internal resources on drug discovery and manufacturing activities. The growing number of virtual biotechnology companies and small biopharmaceutical firms with limited in-house analytical infrastructure continues to strengthen demand for contract analytical testing providers across preclinical, clinical, and commercial development stages.
Market Dynamics
The market continues to benefit from technological advancements in analytical instrumentation, including high-resolution mass spectrometry, next-generation sequencing, automated sample preparation, and digital laboratory information management systems, which improve testing accuracy, throughput, and data integrity while supporting increasingly complex regulatory requirements. Growing pharmaceutical manufacturing activities across emerging economies are further creating demand for regional analytical testing laboratories capable of supporting local regulatory submissions and commercial quality control.
Stringent regulatory expectations, high capital requirements for advanced analytical equipment, and the ongoing need to maintain GMP-, GLP-, and ISO-compliant laboratories increase operational complexity and create barriers for smaller service providers. Expanding development of advanced biologics, biosimilars, cell and gene therapies, and personalized medicines presents significant opportunities for laboratories offering specialized analytical services, while continuous innovation in analytical technologies and rising global outsourcing activity are expected to support long-term market growth.
The growing investment in pharmaceutical and biopharmaceutical research and development is a major driver of the healthcare analytical testing services market. The rising number of small-molecule drugs, biologics, biosimilars, vaccines, antibody-drug conjugates (ADCs), cell and gene therapies, and novel therapeutic candidates entering preclinical and clinical development has substantially increased demand for analytical testing services. Drug developers require comprehensive analytical support for method development, validation, impurity profiling, stability studies, release testing, characterization, and regulatory submissions throughout product development and commercialization. Outsourcing analytical testing enables pharmaceutical and biotechnology companies to reduce operational costs, access specialized expertise, accelerate development timelines, and maintain compliance with evolving regulatory standards. Furthermore, increasing clinical trial activity and the expansion of contract development and manufacturing organizations (CDMOs) continue to generate sustained demand for independent analytical testing laboratories.
Stringent regulatory requirements and the high cost of maintaining advanced analytical laboratories remain key restraints for the healthcare Analytical Testing Services market. Analytical testing laboratories must comply with Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP), ISO standards, and various global regulatory guidelines, requiring continuous investment in quality systems, laboratory accreditation, validation procedures, documentation, and staff training. Advanced analytical instrumentation, including high-resolution mass spectrometry, nuclear magnetic resonance (NMR), chromatography systems, and microbiological testing platforms, involves significant capital expenditure and ongoing maintenance costs. In addition, rapidly evolving regulatory expectations require frequent updates to testing methodologies and quality management systems. These factors increase operational expenses and create barriers for smaller testing laboratories, while delays in regulatory inspections or method validation can extend product development timelines.
The expanding pipeline of biologics, biosimilars, personalized medicines, and advanced therapies presents significant growth opportunities for the healthcare Analytical Testing Services market. Increasing development of monoclonal antibodies, recombinant proteins, vaccines, gene therapies, cell therapies, RNA therapeutics, and antibody-drug conjugates requires highly specialized analytical characterization and quality testing throughout development and commercialization. The growing adoption of outsourcing among emerging biotechnology companies, combined with increasing demand for specialized bioanalytical testing, stability studies, comparability assessments, and biosafety testing, is creating new business opportunities for analytical service providers. Moreover, continued investments in pharmaceutical manufacturing, expansion of CDMO capabilities, and increasing regulatory emphasis on product quality and lifecycle management are expected to drive long-term demand for comprehensive Analytical Testing Services across global healthcare markets.
Market Concentration & Characteristics
The healthcare analytical testing services market growth stage is high, and the pace of growth is accelerating. The market is characterized by the degree of innovation, level of M&A activities, regulatory impact, service expansion, and regional expansion.
Innovation is a key competitive factor in the market, with laboratories continuously investing in advanced analytical instrumentation, automation, artificial intelligence-driven data analysis, and molecular characterization technologies. Growing demand for biologics, biosimilars, cell and gene therapies, and personalized medicines is encouraging the adoption of high-sensitivity analytical platforms that improve testing accuracy and laboratory efficiency. Continuous innovation enables service providers to expand specialized testing capabilities, improve turnaround times, and support evolving regulatory requirements, strengthening their competitive position.
To learn more about this report, Download Free Sample Report Mergers and acquisitions continue to reshape the healthcare analytical testing services industry by expanding laboratory networks, strengthening technical capabilities, and broadening service portfolios. Strategic acquisitions enable analytical testing providers to access specialized expertise in bioanalytical testing, microbiology, material characterization, and advanced therapy testing while expanding their geographic presence. Such transactions also improve operational scale, increase customer reach, and strengthen competitive positioning in a rapidly evolving outsourcing market.
Regulatory compliance remains one of the most influential factors affecting the Healthcare Analytical Testing Services Market. Laboratories must comply with Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP), ISO standards, ICH guidelines, and requirements established by global regulatory authorities. Maintaining validated analytical methods, data integrity, laboratory accreditation, and comprehensive documentation increases operational complexity while creating opportunities for laboratories with strong regulatory expertise and established quality systems.
Healthcare analytical testing providers are expanding their service portfolios to support pharmaceutical, biotechnology, and medical device companies throughout the product lifecycle. Many laboratories now offer integrated services including bioanalytical testing, method development and validation, stability studies, extractables and leachables testing, microbiological testing, elemental impurity analysis, and regulatory support. Broader service capabilities improve customer retention, increase cross-selling opportunities, and enable providers to address a wider range of analytical requirements through a single service partner.
Regional expansion is enabling analytical testing providers to strengthen their presence in high-growth pharmaceutical manufacturing and biotechnology markets. Establishing new laboratories and expanding existing facilities across North America, Europe, Asia Pacific, Latin America, and the Middle East improves customer accessibility, reduces sample transportation timelines, and supports compliance with regional regulatory requirements. A broader laboratory network also enhances business continuity, strengthens global service delivery, and enables providers to support multinational pharmaceutical and medical device companies more effectively.
Analyst Perspective
The healthcare analytical testing services market is experiencing sustained growth driven by rising pharmaceutical and biotechnology research activities, increasing regulatory requirements, and the growing outsourcing of analytical testing services. Pharmaceutical, biopharmaceutical, and medical device manufacturers are increasingly relying on specialized contract testing organizations to support product development, quality control, regulatory submissions, and commercial manufacturing while reducing operational costs and accelerating development timelines.
The rapid expansion of biologics, biosimilars, vaccines, cell and gene therapies, antibody-drug conjugates, and personalized medicines has significantly increased demand for sophisticated analytical techniques, including bioanalytical testing, method development and validation, extractables and leachables studies, stability testing, microbiological testing, and material characterization. At the same time, evolving regulatory expectations from global health authorities are driving continuous investments in laboratory automation, high-resolution analytical instrumentation, digital quality management systems, and data integrity solutions.
Growing outsourcing by pharmaceutical companies, expansion of CDMO and CRO activities, and increasing demand for specialized testing throughout the product lifecycle are creating attractive growth opportunities for analytical service providers. Companies that combine global laboratory infrastructure, advanced analytical capabilities, regulatory expertise, and comprehensive end-to-end testing services are expected to strengthen their competitive position and capture a larger share of the expanding healthcare analytical testing services market over the forecast period.
Impact of U.S. Tariffs on the Global Healthcare Analytical Testing Services Market
The imposition of U.S. tariffs on imported laboratory equipment, analytical instruments, electronic components, and specialty chemicals has increased procurement costs for healthcare analytical testing laboratories. Higher prices for mass spectrometers, chromatography systems, laboratory consumables, and reference standards have elevated capital and operational expenditures for testing service providers. Laboratories dependent on imported reagents and precision components have experienced supply chain disruptions and longer procurement timelines, affecting laboratory efficiency.
Pharmaceutical and biotechnology companies may also face higher analytical testing costs, particularly during method development, stability studies, and bioanalytical testing. Some service providers have responded by diversifying supplier networks, increasing local sourcing, and strengthening inventory management to reduce supply risks. Besides, manufacturers of analytical instruments have expanded regional production and assembly capabilities to mitigate tariff-related cost pressures. Demand for analytical testing services remains continuous, driven by stringent regulatory requirements and continued pharmaceutical R&D investments. The growing outsourcing of analytical testing by drug developers is expected to partially offset rising operating costs. Thus, investments in domestic laboratory infrastructure and localized supply chains are likely to improve market resilience while supporting sustained market growth.
Technological Advancements
Technological advancements are reshaping the healthcare analytical testing services market by improving analytical precision, laboratory efficiency, and regulatory readiness across the pharmaceutical and medical device industries. The growing complexity of biologics, biosimilars, cell and gene therapies, and personalized medicines is driving the need for sophisticated analytical platforms capable of generating reliable, reproducible results. Modern instrumentation enables laboratories to perform highly sensitive characterization, impurity analysis, and product quality assessments with greater confidence. Automation technologies are reducing manual intervention while increasing testing capacity and operational consistency across high-volume laboratories. Digital laboratory platforms improve workflow management, sample traceability, and regulatory documentation, thereby enhancing data integrity and compliance.
To learn more about this report, Download Free Sample Report Artificial intelligence-based analytics is supporting faster interpretation of complex datasets and enabling more efficient optimization of analytical methods. Genomic technologies such as next-generation sequencing are broadening the scope of analytical testing for advanced therapies and molecular diagnostics. These innovations are helping service providers address evolving regulatory expectations while improving turnaround times and resource utilization. Laboratories are increasingly investing in advanced analytical capabilities to support diverse therapeutic modalities throughout development and commercialization. As outsourcing continues to expand across the pharmaceutical value chain, technology-enabled testing services are becoming a critical component of product quality assurance and regulatory success. Continued investments in analytical innovation, laboratory digitalization, and specialized testing capabilities are expected to strengthen the competitive position of analytical service providers and support sustained long-term market growth.
Pricing Model Analysis
The healthcare analytical testing services industry utilizes multiple pricing structures designed to address varying project complexity, testing volumes, and client requirements. Fee-for-service remains the most common model for routine analytical testing, offering transparent pricing for individual assays and laboratory procedures. Project-based pricing is widely adopted for defined development programs with predetermined deliverables and timelines, enabling effective budget planning. Full-time equivalent arrangements are preferred for long-duration analytical programs requiring dedicated scientific personnel and continuous technical support. Master Service Agreements are increasingly being adopted by large pharmaceutical and biotechnology companies seeking standardized pricing, priority laboratory access, and long-term analytical collaboration.
To learn more about this report, Download Free Sample Report The selection of a pricing model is influenced by the product development stage, regulatory requirements, sample volume, analytical complexity, and turnaround expectations. Service providers are also incorporating flexible commercial terms to accommodate changing development priorities and fluctuating testing demand. Long-term contractual engagements are becoming more prevalent as outsourcing continues to expand across the pharmaceutical value chain. This evolution in pricing strategies is improving customer retention, strengthening business continuity, and supporting sustainable revenue generation for analytical testing organizations.
Type Insights
The pharmaceutical analytical testing services segment led the healthcare analytical testing services industry, accounting for the largest revenue share of 58.4% in 2025. The segment dominates the market owing to the increasing development of pharmaceuticals, biologics, biosimilars, vaccines, antibody-drug conjugates, RNA therapeutics, and advanced therapies, all of which require extensive analytical evaluation throughout the product lifecycle. Growing outsourcing by pharmaceutical and biotechnology companies is increasing demand for bioanalytical testing, method development and validation, stability studies, impurity profiling, and batch release testing, enabling developers to accelerate product development while maintaining regulatory compliance.
Stringent quality requirements established by global regulatory authorities are further increasing the need for specialized analytical testing before product approval and commercial manufacturing. The continued expansion of clinical research activities and pharmaceutical manufacturing worldwide is also generating sustained demand for outsourced analytical services. Major testing providers are strengthening their laboratory infrastructure and expanding specialized capabilities to address growing industry requirements. For instance, in March 2025, Labcorp announced the acquisition of select oncology and oncology-related clinical testing assets from BioReference Health, expanding its laboratory testing capabilities and strengthening its pharmaceutical and clinical testing portfolio in the U.S. Similarly, in March 2025, Eurofins completed the acquisition of SYNLAB's clinical diagnostics operations in Spain, strengthening its laboratory network, expanding genetics and pathology testing capabilities, and increasing its annual testing capacity to more than 100 million laboratory tests. Such strategic developments are enhancing analytical capacity, expanding specialized testing services, and supporting the continued leadership of the pharmaceutical analytical testing services segment.
To learn more about this report, Download Free Sample Report The medical device analytical testing services segment is expected to grow at the fastest CAGR during the forecast period. The segment growth is driven by the increasing development of implantable devices, diagnostic equipment, combination products, wearable medical technologies, and minimally invasive devices, all of which require extensive analytical evaluation to ensure safety, performance, and regulatory compliance. Rising regulatory scrutiny associated with biocompatibility, extractables and leachables, material characterization, sterility assurance, and microbiological testing is encouraging manufacturers to outsource specialized analytical services to accredited laboratories. Growing adoption of advanced materials, polymers, and smart medical devices has further increased the need for sophisticated chemical and physical characterization throughout the product lifecycle. Moreover, expanding medical device manufacturing across emerging economies and the increasing number of product approvals are generating sustained demand for analytical testing services. Leading testing organizations are strengthening their capabilities through laboratory expansion and strategic acquisitions to address evolving customer requirements. For instance, in January 2025, SGS expanded its medical device testing capabilities through the acquisition of Gerstel Medizintechnik GmbH, strengthening its expertise in medical device testing, certification, and regulatory compliance across Europe. Such strategic initiatives are expected to support the rapid growth of the medical device analytical testing services segment over the forecast period.
Regional Insights
North America dominated the healthcare analytical testing services market with the largest revenue share of 39.2% in 2025. The regional market is supported by substantial pharmaceutical and biotechnology R&D expenditure, a well-established network of analytical testing laboratories, and the presence of major pharmaceutical manufacturers and contract research organizations. Growing development of biologics, biosimilars, cell and gene therapies, and personalized medicines continues to increase demand for bioanalytical testing, method development and validation, stability studies, and microbiological testing. Besides, stringent regulatory requirements established by the FDA and Health Canada are encouraging pharmaceutical and medical device manufacturers to adopt comprehensive analytical testing throughout product development and commercialization. Increasing outsourcing of analytical testing by pharmaceutical companies seeking specialized expertise, advanced instrumentation, and faster regulatory submissions is further supporting market expansion. Continued investments in laboratory automation, digital laboratory systems, and high-resolution analytical technologies are expected to sustain regional growth over the forecast period.
To learn more about this report, Download Free Sample Report U.S. Healthcare Analytical Testing Services Market Trends
The U.S. healthcare analytical testing services industry led North America, with the largest share in 2025. Market growth is driven by the presence of leading pharmaceutical, biotechnology, and medical device companies, increasing clinical trial activity, and rising demand for outsourced analytical testing services. Growing pipelines of biologics, vaccines, antibody-drug conjugates, and cell and gene therapies are driving demand for specialized analytical services, including bioanalytical testing, stability testing, and extractables and leachables studies. Pharmaceutical manufacturers are increasingly outsourcing analytical activities to improve development timelines, reduce laboratory operating costs, and access advanced testing capabilities. Continued investments by analytical testing providers in laboratory expansion and advanced instrumentation are expected to support long-term market growth.
The Canada healthcare analytical testing services market is expected to grow at a significant CAGR during the forecast period. Growth is supported by increasing pharmaceutical research activities, government funding for life sciences, and the expansion of the country's biotechnology sector. Rising clinical research activity and increasing development of biologics and biosimilars are creating demand for specialized analytical testing services across preclinical, clinical, and commercial stages. Besides, Canada's strong regulatory framework, highly skilled scientific workforce, and expanding laboratory infrastructure continue to attract outsourcing from pharmaceutical and biotechnology companies. Increasing investments in advanced analytical technologies and quality testing capabilities are expected to support market expansion throughout the forecast period.
Europe Healthcare Analytical Testing Services Market Trends
The Europe healthcare analytical testing services industry is experiencing steady growth supported by a mature pharmaceutical industry, increasing biologics development, and stringent regulatory standards governing pharmaceutical and medical device quality. Growing investment in biosimilars, advanced therapies, and vaccine development is increasing demand for analytical characterization, stability studies, microbiological testing, and bioanalytical services. The region also benefits from a strong presence of global analytical testing providers, contract research organizations, and pharmaceutical manufacturers seeking specialized laboratory services. Continued expansion of laboratory infrastructure and increasing outsourcing of analytical testing activities are expected to support market growth over the forecast period.
The healthcare analytical testing services market in Germany held the largest share in Europe in 2025. The country benefits from a strong pharmaceutical manufacturing base, advanced analytical laboratory infrastructure, and significant investment in biologics, biosimilars, and advanced therapeutics. Increasing regulatory requirements related to product quality and safety are driving demand for method validation, impurity profiling, microbiological testing, and stability studies. Growing adoption of advanced analytical instrumentation and continuous investment in research activities are expected to support market expansion during the forecast period.
The UK healthcare analytical testing services market is expected to grow significantly over the forecast period. The market expansion is supported by a strong biotechnology ecosystem, increasing clinical research activities, and the presence of leading contract research organizations and analytical testing laboratories. The growing development of advanced therapies, including cell and gene therapies, monoclonal antibodies, and RNA-based therapeutics, is increasing demand for specialized bioanalytical and biomarker testing services. Besides, continued government support for life sciences research, expansion of laboratory capabilities, and increasing outsourcing by pharmaceutical companies are expected to contribute to sustained market growth.
Asia Pacific Healthcare Analytical Testing Services Market Trends
The Asia Pacific healthcare analytical testing services industry is expected to grow at a significant CAGR over the forecast period. Market growth is supported by expanding pharmaceutical and biotechnology industries, rising clinical research activity, improved laboratory infrastructure, and favorable government initiatives that promote life sciences. The growing outsourcing of analytical testing by global pharmaceutical companies to countries offering skilled scientific talent and competitive operating costs is driving regional demand. Besides, increasing production of biologics, biosimilars, vaccines, and generic medicines is generating higher demand for bioanalytical testing, stability studies, microbiological testing, and method validation services. Continued investment in laboratory modernization and quality systems is expected to support long-term market expansion.
The healthcare analytical testing services market in China is witnessing strong growth due to increasing pharmaceutical manufacturing, expanding biotechnology research, and rising outsourcing by global pharmaceutical companies. Government initiatives supporting innovation, improvements in regulatory standards, and growing investment in biologics and advanced therapies are increasing demand for specialized analytical testing services. Besides, the continuous expansion of GMP-compliant laboratories, the adoption of advanced analytical technologies, and a strong domestic pharmaceutical industry are strengthening China's position as a major analytical testing hub in the Asia Pacific.
The healthcare analytical testing services market in Japan is driven by a well-established pharmaceutical industry, advanced analytical capabilities, and high healthcare expenditure. Increasing development of biologics, regenerative medicines, and precision therapeutics is creating sustained demand for bioanalytical testing, stability testing, and quality control services. Strict regulatory requirements and ongoing investment in advanced laboratory technologies are encouraging pharmaceutical companies to engage specialized analytical testing providers throughout the product lifecycle.
The India healthcare analytical testing services market is experiencing rapid growth, driven by expanding pharmaceutical manufacturing, increasing contract research activities, and a large pool of skilled scientific professionals. The rising production of generic medicines, biosimilars, vaccines, and complex biologics is driving demand for analytical testing across development and commercial manufacturing stages. Besides, government initiatives supporting pharmaceutical innovation, improvements in laboratory infrastructure, and increased outsourcing by global pharmaceutical companies are expected to drive continued market growth.
Latin America Healthcare Analytical Testing Services Market Trends
The Latin America healthcare analytical testing services industry is expected to grow steadily during the forecast period. Growth is supported by increasing pharmaceutical production, expanding clinical trial activity, and rising investment in biotechnology research across the region. Countries including Brazil and Argentina are strengthening laboratory capabilities and attracting outsourcing from multinational pharmaceutical companies seeking cost-effective analytical testing solutions. The increasing regulatory focus on product quality and the greater adoption of international quality standards are expected to contribute to market expansion.
Brazil’s healthcare Analytical Testing Services market growth is driven by growing pharmaceutical manufacturing, increasing biotechnology investment, and supportive government initiatives for healthcare innovation. The rising outsourcing of analytical testing by domestic and international pharmaceutical companies is driving demand for bioanalytical, microbiological, and stability testing services. Continued expansion of laboratory infrastructure, increasing vaccine production, and greater collaboration between local and global life sciences companies are expected to support sustained market growth.
Middle East & Africa Healthcare Analytical Testing Services Market Trends
The Middle East & Africa healthcare analytical testing services industry is expected to grow steadily over the forecast period. The market is supported by increasing healthcare expenditure, expansion of pharmaceutical manufacturing, and growing investment in biotechnology and life sciences. Rising regulatory requirements, increased clinical research activities, and greater adoption of outsourced analytical testing services are driving regional demand. Continued investment in laboratory infrastructure and quality systems is expected to create additional opportunities for analytical testing providers.
The UAE healthcare analytical testing services market is experiencing steady growth, driven by increasing investment in healthcare infrastructure, pharmaceutical manufacturing, and biomedical research. Government initiatives to strengthen the life sciences sector, along with growing demand for high-quality analytical testing services, are driving market expansion. In addition, the increasing adoption of international regulatory standards, expansion of laboratory capabilities, and rising partnerships with global pharmaceutical companies are expected to contribute to long-term market growth.
Key Healthcare Analytical Testing Services Company Insights
The key players operating across the market are adopting strategic initiatives such as service launches, mergers & acquisitions, partnerships & agreements, and expansions to gain a competitive edge in the market. For instance, in May 2025, Intertek expanded its GMP pharmaceutical services laboratory in Melbourne, UK, by adding 6,000 square feet of laboratory space to strengthen analytical testing capabilities for inhaled biologics, mRNA therapeutics, nucleotide-based medicines, and vaccines. The expansion also added advanced mass spectrometry, particle characterization, and cell-based bioassay capabilities to support pharmaceutical drug development.
Key Healthcare Analytical Testing Services Companies
The following key companies have been profiled for this study on the healthcare analytical testing services market.
-
Thermo Fisher Scientific, Inc.
-
ICON plc
-
LabCorp
-
Charles River Laboratories International, Inc.
-
Syneos Health
-
SGS SA
-
Eurofins Scientific
-
Pace Analytical Services, LLC
-
Toxikon, Inc.
-
Intertek Group
Competitive Benchmarking
Operating Strategies
Competitive Edge
Weaknesses
Established Players (Thermo Fisher Scientific, Inc., Eurofins Scientific)
- Mature players in the healthcare analytical testing services market focus on expanding global laboratory networks, broadening analytical service portfolios, and strengthening regulatory compliance capabilities. These companies actively invest in advanced analytical technologies, digital laboratory solutions, acquisitions, and strategic collaborations to provide end-to-end testing services for pharmaceutical, biopharmaceutical, and medical device manufacturers.
- Established players possess strong competitive advantages through extensive laboratory infrastructure, global regulatory expertise, comprehensive testing capabilities, and long-standing relationships with pharmaceutical and medical device companies. Their broad service offerings, experienced scientific workforce, and accredited laboratories enable efficient project execution, faster regulatory support, and high-quality analytical testing across multiple therapeutic areas.
- Mature players often face high operating costs associated with maintaining sophisticated analytical laboratories, complying with regulations, and using advanced instrumentation. Large organizational structures may reduce operational flexibility, while integrating acquisitions and managing global laboratory networks can increase administrative complexity and capital expenditure.
Emerging Players (Pace Analytical Services, LLC, Toxikon, Inc.)
- Emerging players primarily focus on specialized analytical testing services, niche expertise, flexible project execution, and regional laboratory expansion. Many emphasize customized testing solutions, rapid turnaround times, investments in advanced analytical instrumentation, and strategic partnerships with biotechnology companies, medical device manufacturers, and CDMOs to strengthen their market presence.
- Emerging players benefit from operational flexibility, specialized scientific expertise, personalized customer support, and the ability to rapidly adopt new analytical technologies. Their focused service offerings allow them to address complex analytical requirements for emerging biologics, medical devices, and advanced therapies while serving small and mid-sized pharmaceutical companies.
- Emerging companies often face challenges related to limited laboratory capacity, smaller geographic footprints, and comparatively lower financial resources. Many lack comprehensive global regulatory experience and broad service portfolios, making it difficult to compete with multinational testing organizations offering integrated analytical solutions across multiple regions and product categories.
Recent Developments
-
In July 2025, Alliance Pharma acquired UK-based Drug Development Solutions to expand its analytical and bioanalytical service offerings and strengthen its laboratory capabilities for pharmaceutical development.
-
In September 2025, Nelson Labs introduced RapidCert Biological Indicator sterility testing, reducing biological indicator incubation time from seven days to 48 hours through rapid microbiological methods, enabling faster sterility confirmation for pharmaceutical and medical device manufacturers.
Healthcare Analytical Testing Services Market Report Scope
Report Attribute
Details
Market size in 2025
USD 17.0 billion
Estimated market size in 2026
USD 18.4 billion
Projected market size by 2033
USD 32.7 billion
Growth rate
CAGR of 8.5% from 2025 to 2033
Actual Data
2021 - 2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million/billion and CAGR from 2026 to 2033
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Type, region
Regional scope
North America; Europe; Asia Pacific; Latin America; MEA
Country scope
U.S.; Canada; Mexico; Germany; UK; France; Italy; Spain; Norway; Denmark; Sweden; China; Japan; India; South Korea; Australia; Thailand; Brazil; Argentina; Saudi Arabia; South Africa; UAE; Kuwait; Oman; Qatar.
Key companies profiled
Thermo Fisher Scientific, Inc.; ICON plc; LabCorp; Charles River Laboratories International, Inc.; Syneos Healthl SGS SA; Eurofins Scientific; Pace Analytical Services, LLC; Toxikon, Inc.; Intertek Group
Customization scope
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
Global Healthcare Analytical Testing Services Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global healthcare analytical testing services market report based on type and region:
To learn more about this report, Download Free Sample Report -
Type Outlook (Revenue, USD Million/Billion, 2021 - 2033)
-
Medical Device Analytical Testing Services
-
Extractable and Leachable
-
Material Characterization
-
Physical Testing
-
Bioburden Testing
-
Sterility Testing
-
Other Tests
-
-
Pharmaceutical Analytical Testing Services
-
Bioanalytical Testing
-
Method Development and Validation
-
Stability Testing
-
Other Testing Services
-
-
-
Regional Outlook (Revenue, USD Million/Billion, 2021 - 2033)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
-
Asia Pacific
-
Japan
-
China
-
India
-
Australia
-
Thailand
-
South Korea
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East & Africa
-
South Africa
-
UAE
-
Saudi Arabia
-
Kuwait
-
Qatar
-
Oman
-
-
Research Methodology
The healthcare analytical testing services market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each healthcare analytical testing services segment quantified using the revenue-capture definitions in the table below.
Segment Definition
Segment - Type
Revenue capture definition
Medical Device Analytical
Testing Services
The segment captures revenue generated from analytical testing services for medical devices across product development, regulatory approval, manufacturing, and post-market surveillance. Services include chemical characterization, microbiological testing, physical performance evaluation, sterility assessment, packaging validation, and other analytical studies performed to ensure product safety, quality, performance, and regulatory compliance.
Extractable and Leachable
The segment captures revenue generated from extractables and leachables (E&L) testing services performed to identify and quantify chemical compounds that may migrate from medical device materials, packaging, containers, or delivery systems into pharmaceutical products or patients. Services include study design, analytical method development, compound identification, toxicological assessment, and regulatory documentation.
Material Characterization
The segment captures revenue generated from material characterization services used to evaluate the physical, chemical, thermal, and structural properties of raw materials, polymers, metals, ceramics, coatings, and finished medical devices. Services include compositional analysis, spectroscopy, microscopy, elemental analysis, and material-compatibility studies, supporting product development and regulatory submissions.
Physical Testing
The segment captures revenue generated from physical testing services conducted to assess the mechanical, functional, and performance characteristics of medical devices. Services include tensile testing, compression testing, fatigue testing, dimensional analysis, package integrity testing, durability evaluation, and performance verification performed in accordance with regulatory and industry standards.
Bioburden Testing
The segment captures revenue generated from bioburden testing services performed to determine the number and types of viable microorganisms present on medical devices, components, or manufacturing materials before sterilization. Services include microbial enumeration, contamination assessment, method validation, and routine quality control testing supporting sterilization validation and regulatory compliance.
Sterility Testing
The segment captures revenue generated from sterility testing services conducted to verify the absence of viable microorganisms in sterile medical devices and healthcare products. Services include sterility testing, sterilization validation, bacterial endotoxin testing, environmental monitoring, and microbiological quality assessments performed in accordance with pharmacopeial and regulatory guidelines.
Other Tests
The segment captures revenue generated from Analytical Testing Services not included under the primary testing categories. These include packaging validation, shelf-life studies, contamination analysis, failure investigations, cleaning validation, particulate testing, residual analysis, and other specialized analytical services supporting medical device development and commercialization.
Pharmaceutical Analytical
Testing Services
The segment captures revenue generated from Analytical Testing Services provided for pharmaceutical and biopharmaceutical products throughout discovery, development, manufacturing, and commercialization. Services include bioanalytical testing, method development and validation, stability studies, impurity profiling, microbiological testing, release testing, and regulatory support to ensure product quality, safety, efficacy, and compliance.
Bioanalytical Testing
The segment captures revenue generated from bioAnalytical Testing Services used to measure drugs, metabolites, biomarkers, and biological molecules in biological samples. Services include pharmacokinetic (PK), pharmacodynamic (PD), immunogenicity, biomarker analysis, ligand-binding assays, cell-based assays, and LC-MS/MS testing supporting preclinical and clinical drug development.
Method Development
and Validation
The segment captures revenue generated from analytical method development, optimization, transfer, and validation services performed to establish reliable analytical procedures for pharmaceutical products and biologics. Services include method qualification, validation according to ICH and regulatory guidelines, robustness studies, and documentation supporting product development and regulatory submissions.
Stability Testing
The segment captures revenue generated from stability testing services conducted to evaluate the physical, chemical, microbiological, and functional stability of pharmaceutical and biopharmaceutical products under various storage conditions. Services include accelerated, long-term, and stress stability studies, shelf-life determination, degradation analysis, and stability-indicating method development.
Other Testing Services
The segment captures revenue generated from pharmaceutical Analytical Testing Services not classified under the primary categories. These include impurity profiling, elemental impurity testing, extractables and leachables studies, raw material testing, microbiological testing, batch release testing, contamination analysis, environmental monitoring, and other specialized analytical services supporting pharmaceutical quality assurance and regulatory compliance.
Estimation Model
Layer Name
Description
Bottom-Up Revenue Model
Market size is estimated by identifying leading and emerging healthcare analytical testing service providers offering pharmaceutical and medical device analytical testing, including bioanalytical testing, method development and validation, stability testing, extractables and leachables testing, material characterization, sterility testing, and microbiological testing.
Revenue attributable to analytical testing services is derived from annual reports, company presentations, regulatory filings, laboratory service portfolios, and management disclosures.
Individual company revenues are aggregated and validated using industry benchmarks, outsourcing trends, and service-specific market shares.Pharmaceutical & Medical Device R&D Spending Model
Market value is estimated by evaluating global pharmaceutical, biotechnology, and medical device research and development expenditure alongside the proportion allocated to outsourced analytical testing services.
Average analytical testing expenditure is assigned across discovery, preclinical, clinical, manufacturing, and post-approval stages for pharmaceuticals, biologics, biosimilars, vaccines, and medical devices. The aggregated outsourced testing spend is then used to estimate the overall Healthcare Analytical Testing Services market.Drug Development Pipeline Demand Model
Market size is estimated by analyzing the number of pharmaceutical, biologic, biosimilar, vaccine, and medical device products progressing through discovery, preclinical research, clinical trials, regulatory approval, and commercial manufacturing.
Average spending on analytical services—including bioanalytical testing, method development and validation, stability studies, microbiological testing, extractables and leachables testing, and batch release testing—is assigned to each development stage.
The total demand generated across all development programs is aggregated to estimate the market size.Outsourcing Penetration Model
Market value is estimated by assessing the proportion of pharmaceutical companies, biotechnology firms, medical device manufacturers, and contract development and manufacturing organizations (CDMOs) that outsource analytical testing activities to specialized laboratories.
Outsourcing penetration rates are determined through primary interviews, industry publications, company disclosures, and partnership announcements.
These rates are applied to the total analytical testing expenditure across pharmaceutical and medical device development and manufacturing to estimate the addressable Healthcare Analytical Testing Services market.Delivered Customizations
This report has been delivered with the following In-depth customizations
Client Request
Customization Delivered
Value Adds
Regional Expansion & Market Entry Strategy
Developed a region-specific opportunity assessment across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The analysis included evaluation of pharmaceutical and biotechnology R&D activity, clinical trial volumes, regulatory frameworks, laboratory infrastructure, outsourcing trends, availability of skilled analytical professionals, healthcare investments, and the presence of pharmaceutical manufacturing hubs. Recommended priority markets and entry strategies based on market growth potential, customer demand, competitive landscape, and regulatory complexity.
Helps identify the most attractive regions for laboratory expansion, strategic partnerships, acquisitions, and new facility investments while minimizing operational, regulatory, and market-entry risks.
Industry Outlook, Value Chain, and Business Model Assessment
Conducted a comprehensive evaluation of the Healthcare Analytical Testing Services ecosystem, covering analytical instrument suppliers, reference standard providers, contract analytical testing laboratories, pharmaceutical and biotechnology companies, medical device manufacturers, CDMOs, CROs, regulatory agencies, and end users. Assessed prevailing business models, outsourcing trends, revenue streams, pricing dynamics, service differentiation, and value creation opportunities across drug discovery, preclinical development, clinical development, commercial manufacturing, and post-market quality assurance.
Provides a holistic understanding of industry structure, outsourcing dynamics, revenue opportunities, and key success factors, enabling stakeholders to identify high-value opportunities across the analytical testing value chain.
Competitive Benchmarking
Performed detailed benchmarking of leading Healthcare Analytical Testing Service providers based on analytical testing capabilities, laboratory infrastructure, regulatory compliance, accreditations (GLP, GMP, ISO), technology platforms, geographic footprint, turnaround time, service portfolio, expertise in biologics and medical devices, customer base, and strategic collaborations. Included comparative positioning of established global testing organizations and emerging specialized analytical laboratories.
Enables identification of competitive gaps, service differentiation opportunities, strategic partnership targets, and acquisition candidates while supporting long-term market positioning and business growth strategies.
Frequently Asked Questions About This Report
The pharmaceutical analytical testing services segment led with a 58.7% revenue share in 2025.
The bioanalytical testing segment led with a 52.5% revenue share in 2025.
The material characterization segment held the largest revenue share of 24.7% in 2025.
Key players include Thermo Fisher Scientific, Inc., ICON plc, LabCorp, Charles River Laboratories International, Inc., Syneos Health, SGS SA, Eurofins Scientific, Pace Analytical Services, LLC, Toxikon, Inc., Intertek Group, among others.
The global healthcare analytical testing services market size was valued at USD 17.0 billion in 2025 and is estimated at USD 18.4 billion for 2026.
The global healthcare analytical testing services market is expected to grow at a CAGR of 8.5% from 2026 to 2033, reaching USD 32.7 billion by 2033.
Key factors include a rise in outsourcing activities of analytical testing services by pharmaceutical and medical devices companies, an increasing number of clinical trials that require analytical testing, and a growing focus on biosimilars.
North America dominated with a 39.2% revenue share in 2025.
Asia Pacific is the fastest-growing region over the forecast period.
About the Author(s)
Medical Devices Research Team
Healthcare · Medical DevicesThis report was authored by the medical devices research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the medical devices segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs - add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
